Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandra Leary

Showing results (71-80 of 217) with videos related to

Pageof 22
Sort By:
Gynecologic Oncology Reports|October 13, 2017
Is uterine preservation combined with bilateral salpingo-oophorectomy to promote subsequent fertility safe in infiltrative mucinous ovarian cancer?Sebastien Gouy, Marine Saidani, Amandine Maulard, et al.
The Lancet. Haematology|December 21, 2020
Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance databasePierre-Marie Morice, Alexandra Leary, Charles Dolladille, et al.
Journal of Clinical Medicine|May 16, 2020
Analysis of Systemic Inflammatory Factors and Survival Outcomes in Endometrial Cancer Patients Staged I-III FIGO and Treated with Postoperative External RadiotherapyKatarzyna Holub, Fabio Busato, Sebastien Gouy, et al.
Plos Genetics|May 10, 2011
ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1Anita K Dunbier, Helen Anderson, Zara Ghazoui, et al.
Bulletin Du Cancer|March 2, 2023
[Current post-surgical treatment strategies in first-line ovarian cancer]Kaïssa Ouali, Judith Michels, Felix Blanc-Durand, et al.
British Journal of Cancer|May 5, 2026
Changes in Cyclin E1 expression and CCNE1 amplification in high-grade ovarian carcinomas post-PARP inhibitor exposureAlexis Trecourt, Alexander Valent, Elisa Yaniz-Galende, et al.
Cancer Medicine|January 4, 2020
Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary Paget's diseaseZoran Gatalica, Semir Vranic, Božo Krušlin, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 14, 2024
Correlation between peritoneal cancer index and survival in advanced epithelial ovarian cancer with complete resectionClaire Sanson, Alice Roosen, Matthieu Faron, et al.
Gynecologic Oncology|July 13, 2016
Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumorsThibault de la Motte Rouge, Patricia Pautier, Catherine Genestie, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Correlation between peritoneal cancer index and survival in advanced epithelial ovarian cancer with complete resectionClaire Sanson, Alice Roosen, Matthieu Faron, et al.
Pageof 22

Showing results (71-80 of 217) with videos related to

Sort By:
Pageof 22
Gynecologic Oncology Reports|October 13, 2017
Is uterine preservation combined with bilateral salpingo-oophorectomy to promote subsequent fertility safe in infiltrative mucinous ovarian cancer?Sebastien Gouy, Marine Saidani, Amandine Maulard, et al.
The Lancet. Haematology|December 21, 2020
Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance databasePierre-Marie Morice, Alexandra Leary, Charles Dolladille, et al.
Journal of Clinical Medicine|May 16, 2020
Analysis of Systemic Inflammatory Factors and Survival Outcomes in Endometrial Cancer Patients Staged I-III FIGO and Treated with Postoperative External RadiotherapyKatarzyna Holub, Fabio Busato, Sebastien Gouy, et al.
Plos Genetics|May 10, 2011
ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1Anita K Dunbier, Helen Anderson, Zara Ghazoui, et al.
Bulletin Du Cancer|March 2, 2023
[Current post-surgical treatment strategies in first-line ovarian cancer]Kaïssa Ouali, Judith Michels, Felix Blanc-Durand, et al.
British Journal of Cancer|May 5, 2026
Changes in Cyclin E1 expression and CCNE1 amplification in high-grade ovarian carcinomas post-PARP inhibitor exposureAlexis Trecourt, Alexander Valent, Elisa Yaniz-Galende, et al.
Cancer Medicine|January 4, 2020
Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary Paget's diseaseZoran Gatalica, Semir Vranic, Božo Krušlin, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 14, 2024
Correlation between peritoneal cancer index and survival in advanced epithelial ovarian cancer with complete resectionClaire Sanson, Alice Roosen, Matthieu Faron, et al.
Gynecologic Oncology|July 13, 2016
Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumorsThibault de la Motte Rouge, Patricia Pautier, Catherine Genestie, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Correlation between peritoneal cancer index and survival in advanced epithelial ovarian cancer with complete resectionClaire Sanson, Alice Roosen, Matthieu Faron, et al.
Pageof 22